- Home
- SUPN vs FA Comparison
SUPN vs FA Comparison
Compare SUPN & FA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SUPN
- FA
- Stock Information
- Founded
- SUPN 2005
- FA 2003
- Country
- SUPN United States
- FA United States
- Employees
- SUPN N/A
- FA N/A
- Industry
- SUPN Biotechnology: Pharmaceutical Preparations
- FA Business Services
- Sector
- SUPN Health Care
- FA Consumer Discretionary
- Exchange
- SUPN Nasdaq
- FA Nasdaq
- Market Cap
- SUPN 2.6B
- FA 2.8B
- IPO Year
- SUPN 2012
- FA 2021
- Fundamental
- Price
- SUPN $44.80
- FA $15.58
- Analyst Decision
- SUPN Buy
- FA Hold
- Analyst Count
- SUPN 2
- FA 6
- Target Price
- SUPN $43.00
- FA $20.75
- AVG Volume (30 Days)
- SUPN 654.2K
- FA 640.6K
- Earning Date
- SUPN 11-03-2025
- FA 11-11-2025
- Dividend Yield
- SUPN N/A
- FA N/A
- EPS Growth
- SUPN 1411.53
- FA N/A
- EPS
- SUPN 1.14
- FA N/A
- Revenue
- SUPN $665,125,000.00
- FA $1,251,464,000.00
- Revenue This Year
- SUPN $4.84
- FA $84.03
- Revenue Next Year
- SUPN $17.69
- FA $6.00
- P/E Ratio
- SUPN $38.93
- FA N/A
- Revenue Growth
- SUPN 5.55
- FA 65.34
- 52 Week Low
- SUPN $29.16
- FA $12.32
- 52 Week High
- SUPN $46.79
- FA $20.79
- Technical
- Relative Strength Index (RSI)
- SUPN 58.16
- FA 40.64
- Support Level
- SUPN $43.44
- FA $15.47
- Resistance Level
- SUPN $46.72
- FA $16.55
- Average True Range (ATR)
- SUPN 1.08
- FA 0.53
- MACD
- SUPN -0.48
- FA -0.03
- Stochastic Oscillator
- SUPN 40.60
- FA 30.03
About SUPN Supernus Pharmaceuticals Inc.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.
About FA First Advantage Corporation
First Advantage Corp is a provider of global software and data in the Human Resources technology industry. The company leverages proprietary technology and AI across its platforms, data, and APIs to deliver comprehensive background screening, digital identity, and verification solutions driven by innovation, automation, and customer success. Its reportable segments are First Advantage Americas, First Advantage International, and Sterling. Maximum revenue is generated from the First Advantage Americas segment. The group serves customers in over 200 countries and territories, modernising hiring and onboarding on a global scale.